We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Industry Insights

Exploring the Technology Behind a Blood Test for Alzheimer's Disease
Industry Insight

Technology Networks recently spoke to Quanterix's Kevin Hrusovsky to hear more about how the company's technology is being applied in the pursuit of a biomarker for Alzheimer's disease, a progressive neurodegenerative condition for which diagnosis often occurs after the onset of symptoms.

Read More

Breaking Down Barriers in Proteomic-Based Drug Discovery
Industry Insight

SomaLogic recently announced an agreement with the biopharmaceutical company Amgen that aims to advance Amgen's drug discovery and development programs through comprehensive proteomic profiling. We spoke with Roy Smythe to discover what barriers have been holding proteome analysis back, and how the collaboration with Amgen aims to change the landscape of drug discovery.

Read More

Targeting “Undruggable” Proteins by Selectively Controlling mRNA Translation
Industry Insight

Up to 80% of proteins do not possess binding sites suitable for direct binding of small molecule drugs, making them “undruggable”. To overcome this problem, Anima Biotech has developed a platform to identify drugs with the ability to interfere with the production of these “undruggable” proteins, by selectively inhibiting the translation of mRNA.

Read More

Scripps Research Spin-Off Ushers a "New Era" in Vaccinology With Platform Technology
Industry Insight

Scripps Research spin-off company Ufovax employs the single-component self-assembling protein nanoparticle (1c-SApNP®) platform technology, that was created in the laboratory of Professor Jiang Zhu, to address some of the key challenges in modern vaccine development. We spoke with Dr Colette Saccomanno to learn more.

Read More

Towards a Deeper Understanding of the Proteomic Landscape
Industry Insight

At a recent London Proteomics Discussion Group Meeting, Professor Roman Fischer kicked off the event by addressing the apparent "failure" of proteomics to deliver new clinical biomarkers thus far. Technology Networks sat down with Fischer to discuss spatial proteomics, and to expand on some of the key aspects of his research.

Read More

"Technology Dance" Looks Set To Transform the Field of DNA Synthesis
Industry Insight

Codexis and Molecular Assemblies recently announced a partnership through which the companies aim to engineer enzymes that will optimize the process of enzymatic DNA synthesis – an alternative approach to chemical DNA synthesis. Technology Networks spoke with Codexis to find out how this will transform the field of DNA synthesis.

Read More

Moderna's COVID-19 Vaccine Shows Positive Interim Results in Phase I Trial
Industry Insight

One of the COVID-19 vaccine candidates that received fast track designation by the FDA is mRNA-1273, developed by Moderna, a clinical stage biotechnology company. The company has shared the positive interim results from a Phase I clinical trial of the vaccine in The New England Journal of Medicine .

Read More

Driving Speed, Sensitivity and Precision in Modern Proteomics
Industry Insight

Technology Networks spoke with Rohan Thakur, Executive Vice President of Life Sciences Mass Spectrometry at Bruker Daltonics, to discuss the company's latest analytical technologies and their capabilities.

Read More

Optimizing the Discovery of Synthetic Antibodies for SARS-CoV-2
Industry Insight

When the COVID-19 global pandemic was declared in March, Twist Biopharma decided to utilize its synthetic antibody discovery libraries to discover antibodies that could have diagnostic or treatment capabilities. Technology Networks spoke with Aaron Sato, Chief Scientific Officer, Twist Biopharma, to find out more.

Read More

13 COVID-19 Vaccines Are in Human Clinical Trials – What Are They?
Industry Insight

The World Health Organization recognizes that, as of June 22, there are over 140 vaccines against COVID-19 in various stages of development. 13 of those candidates are now in human clinical trials. In this insights piece, we explore what those candidates are, and who is developing them.

Read More

 
Advertisement